When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
RVNC - Revance Therapeutics resubmits DaxibotulinumtoxinA BLA for frown lines
Revance Therapeutics Inc.
Revance Therapeutics (NASDAQ:RVNC) has resubmitted the Biologics License Application for DaxibotulinumtoxinA for moderate to severe glabellar lines. The resubmission follows a Complete Response Letter received in October. The letter noted deficiencies found during an FDA inspection at the company's manufacturing facility. Revance (RVNC) had a Type A meeting with the agency in December. Check out Revance's (RVNC) Q4 2021 earnings.